documents

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

14 rows where docket_id = "FDA-2013-N-1525" sorted by posted_date descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: subtype, posted_date, posted_month, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)

posted_year 3

agency_id 1

id agency_id docket_id title document_type subtype posted_date ▲ posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2013-N-1525-0229 FDA None FDA-2013-N-1525 National Plan to Address Alzheimer's Disease RE: Request for Nomination from Gary Gray Pharmacist dba COMPLEX Supporting & Related Material Background Material 2015-03-23T04:00:00Z 2015 3     2015-03-23T19:37:58Z   0 0 09000064818accea
FDA-2013-N-1525-0207 FDA None FDA-2013-N-1525 Cited Reference Martin-Moreno et al Prolonged Oral Cannabinoid Administration Prevents Neuroinflammation, Lowers b-amyloid Levels and Improves Cognitive Performance in Tg APP 2576 Mice RE: Request for Nomination from Gary Gray Pharmacist dba COMPLEX Supporting & Related Material Background Material 2014-10-17T04:00:00Z 2014 10     2015-03-23T19:51:17Z   0 0 09000064818ad191
FDA-2013-N-1525-0206 FDA None FDA-2013-N-1525 Pacher, Pal et al The Endocannabinoid System as an Emerging Target of Pharmacotherapy RE: Request for Nomination from Gary Gray Pharmacist dba COMPLEX Supporting & Related Material Background Material 2014-10-17T04:00:00Z 2014 10     2015-03-23T19:31:29Z   0 0 09000064818acc5d
FDA-2013-N-1525-0122 FDA None FDA-2013-N-1525 Attachment 1 Cited Article RE: Nomination from Hopkinton Drug Supporting & Related Material Background Material 2014-09-19T04:00:00Z 2014 9     2014-09-19T19:08:09Z   0 0 090000648185c738
FDA-2013-N-1525-0127 FDA None FDA-2013-N-1525 Attachment 6 WHO Guidelines for Indoor Air Quality RE: Nominaton from Hopkinton Drug Supporting & Related Material Background Material 2014-09-19T04:00:00Z 2014 9     2014-09-19T19:27:24Z   0 0 090000648185c7b4
FDA-2013-N-1525-0128 FDA None FDA-2013-N-1525 Attachment 7 Policyholders of America Research Committee Report on Diagnosis and Treatement of C.I.R.S RE: Nomination from Hopkinton Drug Supporting & Related Material Background Material 2014-09-19T04:00:00Z 2014 9     2014-09-19T19:33:52Z   0 0 090000648185c7b6
FDA-2013-N-1525-0120 FDA None FDA-2013-N-1525 Attachment A Bibliography RE: Nomination from Hopkinton Drug Supporting & Related Material Background Material 2014-09-19T04:00:00Z 2014 9     2014-09-19T19:00:55Z   0 0 090000648185c6e5
FDA-2013-N-1525-0121 FDA None FDA-2013-N-1525 Attachment B Letter from Hopkinton Drug Dated August 20, 2014 RE: Nomination from Hopkinton Drug Supporting & Related Material Background Material 2014-09-19T04:00:00Z 2014 9     2014-09-19T19:00:43Z   0 0 090000648185c715
FDA-2013-N-1525-0123 FDA None FDA-2013-N-1525 Attachment 2 Cited Reference RE: Nomination from Hopkinton Drug Supporting & Related Material Background Material 2014-09-19T04:00:00Z 2014 9     2014-09-19T19:07:57Z   0 0 090000648185c74e
FDA-2013-N-1525-0125 FDA None FDA-2013-N-1525 Attachment 4 Transcript RE: Nomination from Hopkinton Drug Supporting & Related Material Background Material 2014-09-19T04:00:00Z 2014 9     2014-09-19T19:12:46Z   0 0 090000648185c786
FDA-2013-N-1525-0124 FDA None FDA-2013-N-1525 Attachment 3 VIP Efficacy Summary RE: Nomination from Hopkinton Drug Supporting & Related Material Background Material 2014-09-19T04:00:00Z 2014 9     2014-09-19T19:07:33Z   0 0 090000648185c769
FDA-2013-N-1525-0126 FDA None FDA-2013-N-1525 Attachment 5 GAO Indoor Mold Report September 2008 RE: Nomination from Hopkinton Drug Supporting & Related Material Background Material 2014-09-19T04:00:00Z 2014 9     2014-09-19T19:20:26Z   0 0 090000648185c7af
FDA-2013-N-1525-0016 FDA None FDA-2013-N-1525 Bulk Drug Substances That May Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act; Revised Request for Nominations Notice Request for Nominations 2014-07-02T04:00:00Z 2014 7 2014-07-02T04:00:00Z 2014-10-01T03:59:59Z 2014-11-02T01:09:57Z 2014-15367 0 0 0900006481787042
FDA-2013-N-1525-0001 FDA None FDA-2013-N-1525 List of Bulk Drug Substances That May Be Used in Pharmacy Compounding; Bulk Drug Substances That May Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act Proposed Rule Withdrawal 2013-12-04T05:00:00Z 2013 12 2013-12-04T05:00:00Z 2014-03-05T04:59:59Z 2014-10-03T01:02:26Z 2013-28979 0 0 09000064814a631f

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options: 

CREATE TABLE documents (
    id TEXT PRIMARY KEY,
    agency_id TEXT,
    docket_id TEXT REFERENCES dockets(id),
    title TEXT,
    document_type TEXT,
    subtype TEXT,
    posted_date TEXT,
    posted_year INTEGER,
    posted_month INTEGER,
    comment_start_date TEXT,
    comment_end_date TEXT,
    last_modified TEXT,
    fr_doc_num TEXT,
    open_for_comment INTEGER,
    withdrawn INTEGER,
    object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;